May 5, 2017 09:19 AM EDT

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

John Carroll

Editor & Founder

Polaris Partners is opening up chapter 8 in its big book of biotech investments.

Managing Partner Dave Barrett announced in a blog post Thursday that the venture group closed on Polaris VIII with $435 million in the bank, $35 million over its target.

That cash will be put to a variety of uses, running from drug development through technology and tech services. And they’ll continue to work with some high profile serial biotech execs and scientists, like Katrine Bosley at Editas and earlier at Avila, Tillman Gerngross at Adimab and GlycoFi, Bob Langer — behind a whole range of companies like Momenta — John Mendlein at Adnexus and Fate and Phillip Sharp at Alnylam and Sirtris.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Armed with a $435M bankroll, Po­laris looks to the next wave of biotech star­tups

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa